revenu million
valu usd unless otherwis note
turn page hcv bic launch near
pipelin matur
view hcv guidanc wash expect higher-than-
expect project opex patent cliff make like trough
nonetheless matur pipelin potenti blockbust strong
hiv fundament growth like enhanc bictegravir launch
substanti oncolog prospect like out-year margin expans
see increas visibl toward lt growth appreci potenti
stori set next chapter adjust target
strong hiv help top- bottom-lin beat outlook posit despit
lumpi genvoya growth remain strong
quarter legaci hiv product atripla truvada show particular
strength without major inventori contribut help drive
revenu beat ep vs consensu highlight
believ strong underli base busi gener avail
caus eros may pressur price/shar ex-u somewhat
expect off-set growth speak launch
potenti bictegravir see resist pill size liver safeti
profil advantag could acceler switch new pt gain vs
hcv diminish focu guidanc help reset revenu base futur
growth despit reason solid perform harvoni vs
con epclusa vs con new hcv
guid look lower evolv expect nearli
expect loss driven entri one bright spot
predict pt start price clariti post disrupt entrant major
miss seem unlik estimate hcv alongsid patent
cliff ex-u hiv letairi make kitchen sink year
declin yescarta expans pipelin launch strong hiv
pipelin oncolog gain increas attent filgotinib nash
ph iii continu matur readout begin -- along
potenti bolt-on bd -- potenti continu shift narr toward
new lt growth driver increment new news call also highlight
promis across rest oft-overlook pipelin
get interim gastric cancer futil analysi show
good initi respons r/r b-cell acut lymphoblast leukemia
model pt adjust updat model estim includ
revenu tax opex project selonsertib launch out-year
hcv estim chang price target
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum reason sustain hiv
convert mani patient bictegravir/f/taf
meaning price declin hcv price share
stabil worsen volum beyond
po filgotinib po nash po axi-
cel target deriv dcf analysi
discount rate termin growth rate post-
better expect hcv share retent long-term hcv
price power despit gener entrant success filgotinib
nash product higher revenu car-t product
would lead upsid estim scenario
potenti dcf base valuat would
competit impact hiv hcv franchis failur
filgotinib nash product axi-cel would lead downsid
estim scenario potenti dcf valuat
would
believ bictegravir posit phase data strong
profil along favor demograph price
dynam underpin good hiv franchis sustain
nearer-term competit
overblown expect maintain strong foundat
valuat though expect hcv declin
disrupt entrant emerg share price
stabil provid predict sustain
patient volum still contribut meaning
cash flow next decad nash
asset filgotinib car-t see sever potenti
blockbust pipelin believ kite deal
help remov overhang reaffirm willing
add potenti transform growth driver
overal expect improv sentiment help drive share
appreci low believ
appropri dcf fair valu
power demograph hiv predict hcv share
price sustain volum enabl
meaning cash flow blockbust potenti pipelin
program filgotinib nash kite acquisit add long-
term revenu potenti addit dimens compani
risk patent expiri competit may impact
lt hiv revenu new hcv competitor like compress
pricing/shar near-term unknown remain nash
competit
decis data ph iii triumeq switch studi
interim analysi ph ii entospletinib studi
cgvhd complet ph ii nivolumab
interim analysi ph ii/iii filgotinib uc studi
complet enrol stellar trial selonsertib nash
data finch filgotinib studi ra axi-cel
producteventtimelinedescovycomplet ph prep nda approvalpdufa phase triumeq switch studi eu analysi ph studi ph ii studi psoriat enrol ph finch studi enrol ph finch studi finch studi ph ii studi ankylos enrol divers studi enrol stellar ph studi ph ii studi selonsertib selonsertib ph ii studi nivolumab gastric endpoint analysi ph ii nash easl ph ii pbc analysi ph ii studi ph ii studi cutan lupu ph ii studi sjogren endpoint ph ii combo studi r/r nuc complet ph ii studi ebola ph ii studi lung transplant ph approv eu aggress pivot ph ii zuma studi r/r indol follow-up data pivot ph ii trial adult ph trial pivot ph ii studi pediatr pivot ph ii r/r mcl trial ph ia studi anti-bcma car-t pivot studi base ph ph ia studi mage solid file tcr target solid nunuc initi ph ii capsid inhibitor initi ph fxr milestonesb/f/taffilgotinibselonsertib anti-bcma axi-cel exhibit pipelin
rheumatoid arhritisphas iiicrohn diseasephas iiiulcer colitisphas iiivari inflammatori diseasesphas iinashphas iiialcohol hepatitisphas iigastr cancerphas iiisolid tumorsphas r/r dlbcl pmbcl tfl eu dlbcl iiiindol nhl iidlbcl mab combo ir/r mcl iiadult pediatr cll inashphas iipbcphas iipscphas nashphas iicgvhdphas iihematolog malignanciesphas iiamlphas iisjogren syndromephas iicutan lupu erythematosusphas iitirabrutinib btk b-cell malignanciesphas nuc ebolaphas iipresatovir fusion inhibitor respiratori syncyti viru rsv phase bet solid tumorsphas curephas bnab hivphas capsid inhibitor hivent phase nunuc hivent phase anti-bcma mmphase imag tumorphas tumorphas imag tumorphas head neck cancerphas gen hematolog malignanciesphas gen hematolog head neck cancerpreclinicalkrassolid tumorpreclinicalhbv epigenet modulatorhbvpreclinicalneoantigenssolid fxr entospletinib selonsertib exhibit incom statement
million except per share antivir hcv harvoni- unit states- europe- international- epclusa- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- bictarvi unit europe- international- unit zydelig- product includ cayston filgotinib prob-adjust prob-adjust selonsertib combo prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand biotechnolog
price target deriv via dcf analysi discount rate termin
growth rate post-taf gener valuat support outperform rate
risk rate price target
risk includ gener hiv entrant competit hcv efficaci safeti risk pipelin
product filgotinib selonsertib axi-cel
gilead leader develop market anti-infect drug approv
product treatment hiv/aid hepat hepat liver pulmonolog
diseas gilead develop pipelin antivir liver diseas immunolog oncolog
gilead extens world-wide sale market infrastructur
